Back to Products
LOT: SYN-23-63723-B
Tirzepatide
Tirzepatide is a synthetic dual incretin agonist targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, with a 39-amino acid sequence based on the native GIP structure. It modulates appetite signaling pathways, enhances glucose-dependent insulin secretion, slows gastric emptying, and engages central hunger pathways. Clinical research has demonstrated significantly greater percentage body weight reduction compared to semaglutide, with substantial effects on HbA1c in type 2 diabetes models. It represents a next-generation metabolic research compound exploring multi-pathway incretin biology, insulin sensitivity, and energy balance regulation in both preclinical and clinical settings.
Research Benefits
- Modulates appetite and satiety signaling through dual GLP-1 and GIP receptor agonism, supporting caloric intake regulation in research models
- Enhances glucose-dependent insulin secretion and improves insulin sensitivity, demonstrating superior HbA1c reduction compared to GLP-1 monotherapy
- Supports significant body weight reduction and body composition changes across metabolic and obesity research frameworks
Size
Quantity
Total Price$71.56
Tirzepatide is a synthetic dual incretin agonist peptide structurally based on the native GIP sequence and modified to achieve potent activity at both GLP-1 and GIP receptors. It was developed as part of next-generation metabolic research aimed at expanding beyond single-receptor GLP-1 agonism. Since its development, tirzepatide has been studied extensively in controlled clinical and preclinical settings for its potential influence on glucose regulation, appetite signaling, body composition, and multi-pathway metabolic dynamics.